{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:33:03Z","timestamp":1784111583173,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006506","name":"Brazilian Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006507","name":"Fiocruz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pre-Exposure Prophylaxis (PrEP) has demonstrated efficacy in the reduction of sexually transmitted HIV infections. The prolonged use of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) co-formulation (TDF\/FTC), however, may result in augmented risk of renal toxicity. We aimed to evaluate changes in the estimated Glomerular Filtration Rate (eGFR) in a real-world population setting of participants enrolled in <jats:italic>PrEP Brazil<\/jats:italic>, a 48-week prospective, open-label, demonstration study to assess the feasibility of daily oral TDF\/FTC used by men who have sex with men and transgender women at high-risk of HIV infection, all over 18\u00a0years old.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Kidney function was assessed by serial measurement of serum creatinine and eGFR with the Modification of Diet in Renal Disease Study (MDRD) formula on weeks 4, 12, 24, 36 and 48. Adherence to PrEP was assessed by dosing TDF concentration in dried blood spots at weeks 4 and 48, measured by liquid chromatography-mass spectrometry or mass spectrometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 392 participants completing the 48-week follow-up protocol with TDF blood detectable levels and eGFR measures, 43.1% were young adults, of Caucasian ethnic background (57.9%), with BMI below 30\u00a0kg\/m<jats:sup>2<\/jats:sup>, without arterial hypertension. At screening, median eGFR was 93.0\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup>. At week 4 follow-up, 90 (23% of the study population) participants presented reductions in eGFR greater than 10\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup> as compared to baseline eGFR, some as large as 59\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, but with no clinical outcomes (adverse events and renal adverse events) severe enough to demand TDF\/FTC discontinuation. A negative relationship was observed between TDF blood levels and eGFR at weeks 4 (r\u2009=\u2009\u2212\u00a00.005; p\u2009&lt;\u20090.01) and 48 (r\u2009=\u2009\u2212\u00a00.006; p\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results suggest that the renal function profile in individuals on TDF\/FTC may be assessed on week 4 and then only annually, allowing a more flexible medical follow-up in primary care centers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-022-00437-4","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T12:03:01Z","timestamp":1645704181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Kidney function and daily emtricitabine\/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil"],"prefix":"10.1186","volume":"19","author":[{"given":"Karla Cristina Silva","family":"Petruccelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djane Clarys","family":"Ba\u00eda-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Santos","family":"Val\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Cubas-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Vilhena","family":"Silva-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Carvalho","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Wagner","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuri Costa","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Valdez","family":"Madruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esper G.","family":"Kallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo R.","family":"Alencastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Hoagland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdil\u00e9a Gon\u00e7alves Veloso","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vin\u00edcius Guimar\u00e3es","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"437_CR1","unstructured":"UNAIDS. 2020 Global AIDS Update\u2014Seizing the Moment -Tackling entrenched inequalities to end epidemics. Geneva; 2020."},{"key":"437_CR2","doi-asserted-by":"crossref","unstructured":"Desai M, Field N, Grant R, McCormack S. Recent advances in pre-exposure prophylaxis for HIV. BMJ. 2017;359.","DOI":"10.1136\/bmj.j5011"},{"issue":"4","key":"437_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","volume":"4","author":"V Pilkington","year":"2018","unstructured":"Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J virus Erad [Internet]. 2018;4(4):215\u201324.","journal-title":"J virus Erad [Internet]."},{"issue":"3","key":"437_CR4","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2352-3018(18)30008-0","volume":"5","author":"B Grinsztejn","year":"2018","unstructured":"Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136\u201345.","journal-title":"Lancet HIV"},{"issue":"9","key":"437_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-014-1712-z","volume":"70","author":"A Jafari","year":"2014","unstructured":"Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: Incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70(9):1029\u201340.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"437_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1468-1293.2006.00349.x","volume":"7","author":"A Winston","year":"2006","unstructured":"Winston A, Amin J, Mallon PWG, Marriott D, Carr A, Cooper DA, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7(2):105\u201311.","journal-title":"HIV Med"},{"issue":"1","key":"437_CR7","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","volume":"3","author":"A Mocroft","year":"2016","unstructured":"Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23-32.","journal-title":"Lancet HIV"},{"issue":"2","key":"437_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamainternmed.2014.6786","volume":"175","author":"KK Mugwanya","year":"2015","unstructured":"Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, et al. Changes in glomerular kidney function among hiv-1- uninfected men andwomen receiving emtricitabine- tenofovir disoproxil fumarate preexposure prophylaxis a randomized clinical trial. JAMA Intern Med. 2015;175(2):246\u201354.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"437_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/infdis\/jiw125","volume":"214","author":"K Mugwanya","year":"2016","unstructured":"Mugwanya K, Baeten JM, Celum C, Donnell D, Nickolas T, Mugo N, et al. Low risk of proximal tubular dysfunction associated with emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis in men and women. J Infect Dis. 2016;214(7):1050\u20137.","journal-title":"J Infect Dis"},{"issue":"4","key":"437_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/QAI.0000000000000868","volume":"71","author":"K Mugwanya","year":"2016","unstructured":"Mugwanya K, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A BJ for the PPST. Reversibility of glomerular renal function decline in HIV uninfected men and women discontinuing emtricitabine- tenofovir disoproxil fumarate pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2016;71(4):374\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"437_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7448\/IAS.20.1.21472","volume":"20","author":"B Hoagland","year":"2017","unstructured":"Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, et al. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc [Internet]. 2017;20(1):1\u201314. https:\/\/doi.org\/10.7448\/IAS.20.1.21472.","journal-title":"J Int AIDS Soc [Internet]."},{"key":"437_CR12","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Plano Nacional de Enfrentamento da Epidemia de Aids e das DST entre Gays, HSH e Travestis. Plano Nac Enfrentamento da Epidemia Aids e das DST entre Gays, HSH e Travestis [Internet]. 2007;37."},{"key":"437_CR13","unstructured":"BRASIL. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de Aten\u00e7\u00e3o B\u00e1sica. HIV\/Aids hepatites e outras D. Manual t\u00e9cnico para o diagn\u00f3stico da infec\u00e7\u00e3o pelo HIV em adultos e crian\u00e7as. Manual T\u00e9cnico para o Diagn\u00f3stico da Infec\u00e7\u00e3o pelo HIV em Adultos e Crian\u00e7as. Brasilia. Brasil. 2018. 148 p."},{"issue":"02","key":"437_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/aid.2012.0089","volume":"29","author":"JR Castillo-mancilla","year":"2013","unstructured":"Castillo-mancilla JR, Zheng J, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(02):384\u201390.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"437_CR15","first-page":"391","volume":"10","author":"M Jaffe","year":"1886","unstructured":"Jaffe M. About the precipitate which picric acid produces in normal urine and about a new reaction of creatinine. J Physiol Chem. 1886;10(5):391\u2013400.","journal-title":"J Physiol Chem"},{"issue":"6","key":"437_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"1","key":"437_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, el Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int [Internet]. 2011;80(1):17\u201328. https:\/\/doi.org\/10.1038\/ki.2010.483.","journal-title":"Kidney Int [Internet]."},{"issue":"1","key":"437_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2012.113905","volume":"309","author":"KM Flegal","year":"2013","unstructured":"Flegal KM, Kit BK, Orpana H. Association of all-cause mortality with overweight and obesity using standard body mass index categories a systematic review and meta-analysis. JAMA J Am Med Assoc. 2013;309(1):71\u201382.","journal-title":"JAMA J Am Med Assoc"},{"issue":"19","key":"437_CR19","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Pr. J Am Coll Cardiol. 2018;71(19):e127-248.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"437_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0210106","volume":"14","author":"D Drak","year":"2019","unstructured":"Drak D, Barratt H, Templeton DJ, O\u2019Connor CC, Gracey DM. Renal function and risk factors for renal disease for patients receiving HIV preexposure prophylaxis at an inner metropolitan health service. PLoS ONE. 2019;14(1):1\u201311.","journal-title":"PLoS ONE"},{"issue":"11","key":"437_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2352-3018(16)30153-9","volume":"3","author":"M Gandhi","year":"2016","unstructured":"Gandhi M, Diseases I, Medicine G, Francisco S, Glidden D, Francisco S, et al. HHS Public Access: age, baseline kidney function, and medication exposure are associated withdeclines in creatinine clearance on PrEP: an observational cohort study. Lancet HIV. 2016;3(11):1\u201318.","journal-title":"Lancet HIV"},{"issue":"2","key":"437_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jia2.25420","volume":"23","author":"G Liegeon","year":"2020","unstructured":"Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I, et al. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate\u2014emtricitabine for HIV pre-exposure prophylaxis. J Int AIDS Soc. 2020;23(2):1\u201310.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"437_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/QAD.0000000000000156","volume":"28","author":"MM Solomon","year":"2014","unstructured":"Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine\/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851\u20139.","journal-title":"AIDS"},{"issue":"12","key":"437_CR24","doi-asserted-by":"publisher","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw open. 2019;2(12):e1918169.","journal-title":"JAMA Netw open"},{"issue":"5","key":"437_CR25","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ekir.2018.05.011","volume":"3","author":"F Wang","year":"2018","unstructured":"Wang F, He K, Wang J, Zhao MH, Li Y, Zhang L, et al. Prevalence and risk factors for CKD: a comparison between the adult populations in China and the United States. Kidney Int Reports. 2018;3(5):1135\u201343.","journal-title":"Kidney Int Reports"},{"issue":"2","key":"437_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1053\/j.ajkd.2013.08.028","volume":"63","author":"W Yang","year":"2014","unstructured":"Yang W, Xie D, Anderson AH, Joffe MM, Greene T, Teal V, et al. Association of kidney disease outcomes with risk Factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis [Internet]. 2014;63(2):236\u201343. https:\/\/doi.org\/10.1053\/j.ajkd.2013.08.028.","journal-title":"Am J Kidney Dis [Internet]."},{"issue":"2","key":"437_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/QAI.0000000000001575","volume":"77","author":"KK Mugwanya","year":"2018","unstructured":"Mugwanya KK, Baeten JM, Wyatt C, et al. Frequency of monitoring kidney function in HIV-uninfected persons using daily oral tenofovir disoproxil fumarate pre- exposure prophylaxis Kenneth. J Acquir Immune Defic Syndr. 2018;77(2):206\u201311.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"437_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"437_CR29","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1097\/QAD.0b013e32834bba87","volume":"25","author":"SME Vrouenraets","year":"2011","unstructured":"Vrouenraets SME, Fux CA, Wit FWNM, Hoek FJ, Abeling NGGM, Krediet RT. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 2011;25:2149.","journal-title":"AIDS"},{"issue":"3","key":"437_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1310\/hct1503-87","volume":"15","author":"P Maggi","year":"2014","unstructured":"Maggi P, Montinaro V, Rusconi S, Di Biagio A, Bellagamba R, Bonfanti P, et al. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin Trials. 2014;15(3):87\u201391.","journal-title":"HIV Clin Trials"},{"issue":"9","key":"437_CR31","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2215\/CJN.01700218","volume":"13","author":"SB Ascher","year":"2018","unstructured":"Ascher SB, Scherzer R, Estrella MM, Zhang WR, Muiru AN, Jotwani V, et al. Association of urinary biomarkers of kidney injury with estimated GFR decline in HIV-infected individuals following tenofovir disoproxil fumarate initiation. Clin J Am Soc Nephrol. 2018;13(9):1321\u20139.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-022-00437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T12:08:08Z","timestamp":1645704488000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-022-00437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1186\/s12981-022-00437-4","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PrEP Brazil protocol was approved by the Brazilian National Ethics Review Board (CONEP) (CAAE 08405912.9.1001.5262), and by all the individual sites\u2019 boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}